Cargando…
CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
Significant progress has been achieved in the realm of therapeutic interventions for multiple myeloma (MM), leading to transformative shifts in its clinical management. While conventional modalities such as surgery, radiotherapy, and chemotherapy have improved the clinical outcomes, the overarching...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674477/ https://www.ncbi.nlm.nih.gov/pubmed/38006053 http://dx.doi.org/10.3390/vaccines11111721 |
_version_ | 1785149712569991168 |
---|---|
author | Mishra, Abhinava K. Gupta, Ashna Dagar, Gunjan Das, Dayasagar Chakraborty, Abhijit Haque, Shabirul Prasad, Chandra Prakash Singh, Archana Bhat, Ajaz A. Macha, Muzafar A. Benali, Moez Saini, Kamal S. Previs, Rebecca Ann Saini, Deepak Saha, Dwaipayan Dutta, Preyangsee Bhatnagar, Aseem Rai Darswal, Mrinalini Shankar, Abhishek Singh, Mayank |
author_facet | Mishra, Abhinava K. Gupta, Ashna Dagar, Gunjan Das, Dayasagar Chakraborty, Abhijit Haque, Shabirul Prasad, Chandra Prakash Singh, Archana Bhat, Ajaz A. Macha, Muzafar A. Benali, Moez Saini, Kamal S. Previs, Rebecca Ann Saini, Deepak Saha, Dwaipayan Dutta, Preyangsee Bhatnagar, Aseem Rai Darswal, Mrinalini Shankar, Abhishek Singh, Mayank |
author_sort | Mishra, Abhinava K. |
collection | PubMed |
description | Significant progress has been achieved in the realm of therapeutic interventions for multiple myeloma (MM), leading to transformative shifts in its clinical management. While conventional modalities such as surgery, radiotherapy, and chemotherapy have improved the clinical outcomes, the overarching challenge of effecting a comprehensive cure for patients afflicted with relapsed and refractory MM (RRMM) endures. Notably, adoptive cellular therapy, especially chimeric antigen receptor T-cell (CAR-T) therapy, has exhibited efficacy in patients with refractory or resistant B-cell malignancies and is now also being tested in patients with MM. Within this context, the B-cell maturation antigen (BCMA) has emerged as a promising candidate for CAR-T-cell antigen targeting in MM. Alternative targets include SLAMF7, CD38, CD19, the signaling lymphocyte activation molecule CS1, NKG2D, and CD138. Numerous clinical studies have demonstrated the clinical efficacy of these CAR-T-cell therapies, although longitudinal follow-up reveals some degree of antigenic escape. The widespread implementation of CAR-T-cell therapy is encumbered by several barriers, including antigenic evasion, uneven intratumoral infiltration in solid cancers, cytokine release syndrome, neurotoxicity, logistical implementation, and financial burden. This article provides an overview of CAR-T-cell therapy in MM and the utilization of BCMA as the target antigen, as well as an overview of other potential target moieties. |
format | Online Article Text |
id | pubmed-10674477 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106744772023-11-16 CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond Mishra, Abhinava K. Gupta, Ashna Dagar, Gunjan Das, Dayasagar Chakraborty, Abhijit Haque, Shabirul Prasad, Chandra Prakash Singh, Archana Bhat, Ajaz A. Macha, Muzafar A. Benali, Moez Saini, Kamal S. Previs, Rebecca Ann Saini, Deepak Saha, Dwaipayan Dutta, Preyangsee Bhatnagar, Aseem Rai Darswal, Mrinalini Shankar, Abhishek Singh, Mayank Vaccines (Basel) Review Significant progress has been achieved in the realm of therapeutic interventions for multiple myeloma (MM), leading to transformative shifts in its clinical management. While conventional modalities such as surgery, radiotherapy, and chemotherapy have improved the clinical outcomes, the overarching challenge of effecting a comprehensive cure for patients afflicted with relapsed and refractory MM (RRMM) endures. Notably, adoptive cellular therapy, especially chimeric antigen receptor T-cell (CAR-T) therapy, has exhibited efficacy in patients with refractory or resistant B-cell malignancies and is now also being tested in patients with MM. Within this context, the B-cell maturation antigen (BCMA) has emerged as a promising candidate for CAR-T-cell antigen targeting in MM. Alternative targets include SLAMF7, CD38, CD19, the signaling lymphocyte activation molecule CS1, NKG2D, and CD138. Numerous clinical studies have demonstrated the clinical efficacy of these CAR-T-cell therapies, although longitudinal follow-up reveals some degree of antigenic escape. The widespread implementation of CAR-T-cell therapy is encumbered by several barriers, including antigenic evasion, uneven intratumoral infiltration in solid cancers, cytokine release syndrome, neurotoxicity, logistical implementation, and financial burden. This article provides an overview of CAR-T-cell therapy in MM and the utilization of BCMA as the target antigen, as well as an overview of other potential target moieties. MDPI 2023-11-16 /pmc/articles/PMC10674477/ /pubmed/38006053 http://dx.doi.org/10.3390/vaccines11111721 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mishra, Abhinava K. Gupta, Ashna Dagar, Gunjan Das, Dayasagar Chakraborty, Abhijit Haque, Shabirul Prasad, Chandra Prakash Singh, Archana Bhat, Ajaz A. Macha, Muzafar A. Benali, Moez Saini, Kamal S. Previs, Rebecca Ann Saini, Deepak Saha, Dwaipayan Dutta, Preyangsee Bhatnagar, Aseem Rai Darswal, Mrinalini Shankar, Abhishek Singh, Mayank CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond |
title | CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond |
title_full | CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond |
title_fullStr | CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond |
title_full_unstemmed | CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond |
title_short | CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond |
title_sort | car-t-cell therapy in multiple myeloma: b-cell maturation antigen (bcma) and beyond |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674477/ https://www.ncbi.nlm.nih.gov/pubmed/38006053 http://dx.doi.org/10.3390/vaccines11111721 |
work_keys_str_mv | AT mishraabhinavak cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT guptaashna cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT dagargunjan cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT dasdayasagar cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT chakrabortyabhijit cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT haqueshabirul cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT prasadchandraprakash cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT singharchana cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT bhatajaza cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT machamuzafara cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT benalimoez cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT sainikamals cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT previsrebeccaann cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT sainideepak cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT sahadwaipayan cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT duttapreyangsee cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT bhatnagaraseemrai cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT darswalmrinalini cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT shankarabhishek cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond AT singhmayank cartcelltherapyinmultiplemyelomabcellmaturationantigenbcmaandbeyond |